Skip to main content
CLGN
NASDAQ Industrial Applications And Services

CollPlant Secures $2.0M Registered Direct Offering at Premium to Market Price

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.19
Mkt Cap
$20.473M
52W Low
$1.3
52W High
$4.98
52W Position info
8.5% below low
Off High info
76% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CLGN is trading near its 52-week low of $1.3 (8.5% below the low).

Summary

CollPlant Biotechnologies announced a $2.0 million registered direct offering of ordinary shares at $1.25 per share, a premium to its current trading price, along with concurrent private placement of warrants.


Key Events · Financing and Capital Events · CLGN

  • Secures $2.0 Million Capital

    CollPlant announced a registered direct offering to raise approximately $2.0 million in gross proceeds.

  • Offering Priced at Premium

    Ordinary shares were sold at $1.25 per share, which is above the current market price of $1.19.

  • Concurrent Warrant Issuance

    The offering includes a concurrent private placement of unregistered Series A and Series B warrants, each to purchase up to 1,600,000 ordinary shares at an exercise price of $1.25 per share.

  • Funds General Corporate Purposes

    Net proceeds will be used for general corporate purposes, including working capital and funding research and development programs.


Analysis · CLGN · Industrial Applications And Services

This financing event is significant for CollPlant Biotechnologies, a company with a relatively small market capitalization, especially as it is trading near its 52-week lows. The ability to secure $2.0 million in gross proceeds through a registered direct offering, with shares priced at $1.25, represents a premium to the current market price of $1.19. This suggests institutional confidence in the company's prospects despite its recent stock performance. The offering also includes concurrent private placement of warrants, which introduces substantial potential future dilution if exercised, but also provides additional capital if the stock price rises. The proceeds are earmarked for general corporate purposes, including working capital and R&D, which is crucial for extending the company's operational runway and advancing its regenerative medicine programs. This filing finalizes the terms of the shelf registration statement filed on January 9, 2026.

At the time of this filing, CLGN was trading at $1.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $1.30 to $4.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLGN - Latest Insights

CLGN
Jul 28, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.3278
Real-time Price: $0.3206 info
Change: -$0.0072 (-2%) info
Market Cap: $6.198M info
CLGN
Jul 27, 2026, 4:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.305
Real-time Price: $0.3206 info
Change: +$0.0156 (+5%) info
Market Cap: $6.198M info
CLGN
Jul 09, 2026, 4:25 PM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $0.3587
Real-time Price: $0.3206 info
Change: -$0.0381 (-11%) info
Market Cap: $6.198M info
CLGN
Jul 07, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.360
Real-time Price: $0.3206 info
Change: -$0.0394 (-11%) info
Market Cap: $6.198M info
CLGN
Jul 01, 2026, 8:36 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.343
Real-time Price: $0.3206 info
Change: -$0.0224 (-7%) info
Market Cap: $6.198M info